The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.
阿昔替尼联合帕博利珠单抗激活的自体DC-CIK细胞免疫疗法治疗晚期肾细胞癌患者的疗效和安全性：一项2期研究
期刊:Clinical & Translational Immunology
影响因子:3.8
doi:10.1002/cti2.1257
Song Meng-Jia, Pan Qiu-Zhong, Ding Ya, Zeng Jianxiong, Dong Pei, Zhao Jing-Jing, Tang Yan, Li Jingjing, Zhang Zhiling, He Junyi, Yang Jieying, Huang Yue, Peng Ruiqing, Wang Qi-Jing, Gu Jia-Mei, He Jia, Li Yong-Qiang, Chen Shi-Ping, Huang Rongxing, Zhou Zi-Qi, Yang Chaopin, Han Yulong, Chen Hao, Liu Heping, Xia Shangzhou, Wan Yang, Weng De-Sheng, Xia Liming, Zhou Fang-Jian, Xia Jian-Chuan
